21st July 2026
16th July 2026
Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV400
15th June 2026
Reunion Neuroscience Announces Appointment of Sahil V. Kirpekar, M.D., as President and CEO
8th June 2026
Johnson & Johnson to Acquire Firefly Bio, Inc.
6th June 2026
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
21st May 2026
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
20th May 2026
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
19th May 2026
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
4th May 2026
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
30th April 2026